Dengue viruses (DENV) are endemic pathogens of tropical and subtropical regions that cause significant morbidity and mortality worldwide. To date, no vaccines or antiviral therapeutics have been approved for combating DENV-associated disease. In this paper, we describe a class of tricyclic small-molecule compounds-dihydrodibenzothiepines (DHBTs), identified through highthroughput screening-with potent inhibitory activity against DENV serotype 2. SKI-417616, a highly active representative of this class, displayed activity against all four serotypes of DENV, as well as against a related flavivirus, West Nile virus (WNV), and an alphavirus, Sindbis virus (SINV). This compound was characterized to determine its mechanism of antiviral activity. Investigation of the stage of the viral life cycle affected revealed that an early event in the life cycle is inhibited. Due to the structural similarity of the DHBTs to known antagonists of the dopamine and serotonin receptors, we explored the roles of two of these receptors, serotonin receptor 2A (5HTR2A) and the D4 dopamine receptor (DRD4), in DENV infection. Antagonism of DRD4 and subsequent downstream phosphorylation of epidermal growth factor receptor (EGFR)-related kinase (ERK) were found to impact DENV infection negatively, and blockade of signaling through this network was confirmed as the mechanism of anti-DENV activity for this class of compounds. T he dengue viruses (DENV) are mosquito-borne viruses of the family Flaviviridae that comprise four antigenically distinct serotypes (DENV1 to -4). DENV is an emerging pathogen that is endemic in tropical and subtropical regions. Estimates of the annual number of DENV infections range from 50 million to more than 230 million, resulting in approximately 500,000 to 2 million cases of dengue hemorrhagic fever (DHF) per year (1-3; http: //www.cdc.gov/dengue/). Increased frequency of travel, environmental changes, and expansion of human populations into regions where the primary DENV vector, Aedes aegypti, is prevalent have contributed to the emerging nature of this pathogen (4). Primary infection by a single serotype can result in a range of disease severities, which can include asymptomatic infection; dengue fever, a flu-like illness characterized by prolonged fever and severe joint pain; and severe dengue, or DHF/dengue shock syndrome (DSS), which often presents with hemorrhagic symptoms and thrombocytopenia and can be fatal. It is generally believed that while one is protected from secondary infection with a strain of the same serotype, secondary infection with a heterologous strain predisposes one to the more severe forms of dengue disease (5). Currently, no approved vaccine is available, and treatment for DENV infection consists primarily of supportive therapy.Transmission of DENV to a human host is initiated through the bite of an infected mosquito. Uptake by skin-resident Langerhans cells promotes transport to draining lymph nodes, where the virus then infects dendritic cells, monocytes, and macrophages, allowin...